Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
Epidermal growth factor receptor ( EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to EGFR tyrosine kinase inhibitors (TKIs). First-generation reversible EGFR TKIs, gefitinib and erlotinib have been proven...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-10-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/1753466618808659 |
| _version_ | 1819176051196035072 |
|---|---|
| author | Biagio Ricciuti Sara Baglivo Andrea De Giglio Rita Chiari |
| author_facet | Biagio Ricciuti Sara Baglivo Andrea De Giglio Rita Chiari |
| author_sort | Biagio Ricciuti |
| collection | DOAJ |
| description | Epidermal growth factor receptor ( EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to EGFR tyrosine kinase inhibitors (TKIs). First-generation reversible EGFR TKIs, gefitinib and erlotinib have been proven to improve the objective response rate and to prolong the progression-free survival compared with standard chemotherapy in large phase III trials. Unfortunately, virtually all patients develop resistance to treatment, usually within 9–12 months. Afatinib is an irreversible ErbB family inhibitor initially designed to overcome the development of resistance. Compared with gefitinib in a first-line setting, afatinib prolonged progression-free survival and time to treatment failure, without impacting on overall survival in the general population of EGFR -mutant patients. However, afatinib has been shown to prolong overall survival in the subset of patients with an EGFR exon 19 deletion compared with chemotherapy. The aim of this review is to summarize the clinical evidence available to date and to critically discuss the place in therapy of afatinib in the rapidly expanding landscape of EGFR -mutant NSCLC first-line therapy. |
| first_indexed | 2024-12-22T21:04:37Z |
| format | Article |
| id | doaj.art-dfb65a57cb694fc79160b9ac16cdf376 |
| institution | Directory Open Access Journal |
| issn | 1753-4666 |
| language | English |
| last_indexed | 2024-12-22T21:04:37Z |
| publishDate | 2018-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Respiratory Disease |
| spelling | doaj.art-dfb65a57cb694fc79160b9ac16cdf3762022-12-21T18:12:43ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662018-10-011210.1177/1753466618808659Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experienceBiagio RicciutiSara BaglivoAndrea De GiglioRita ChiariEpidermal growth factor receptor ( EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to EGFR tyrosine kinase inhibitors (TKIs). First-generation reversible EGFR TKIs, gefitinib and erlotinib have been proven to improve the objective response rate and to prolong the progression-free survival compared with standard chemotherapy in large phase III trials. Unfortunately, virtually all patients develop resistance to treatment, usually within 9–12 months. Afatinib is an irreversible ErbB family inhibitor initially designed to overcome the development of resistance. Compared with gefitinib in a first-line setting, afatinib prolonged progression-free survival and time to treatment failure, without impacting on overall survival in the general population of EGFR -mutant patients. However, afatinib has been shown to prolong overall survival in the subset of patients with an EGFR exon 19 deletion compared with chemotherapy. The aim of this review is to summarize the clinical evidence available to date and to critically discuss the place in therapy of afatinib in the rapidly expanding landscape of EGFR -mutant NSCLC first-line therapy.https://doi.org/10.1177/1753466618808659 |
| spellingShingle | Biagio Ricciuti Sara Baglivo Andrea De Giglio Rita Chiari Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience Therapeutic Advances in Respiratory Disease |
| title | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience |
| title_full | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience |
| title_fullStr | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience |
| title_full_unstemmed | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience |
| title_short | Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience |
| title_sort | afatinib in the first line treatment of patients with non small cell lung cancer clinical evidence and experience |
| url | https://doi.org/10.1177/1753466618808659 |
| work_keys_str_mv | AT biagioricciuti afatinibinthefirstlinetreatmentofpatientswithnonsmallcelllungcancerclinicalevidenceandexperience AT sarabaglivo afatinibinthefirstlinetreatmentofpatientswithnonsmallcelllungcancerclinicalevidenceandexperience AT andreadegiglio afatinibinthefirstlinetreatmentofpatientswithnonsmallcelllungcancerclinicalevidenceandexperience AT ritachiari afatinibinthefirstlinetreatmentofpatientswithnonsmallcelllungcancerclinicalevidenceandexperience |